The three clinical studies behind Transfer Factor Max, in plain English

Three studies are routinely cited for 4Life Transfer Factor® Max: Yu et al. (2024), Jensen (2026) and Gardner (2026). They are cited so consistently, and in such compressed form, that most readers encounter them as a bare list of three surnames functioning as a credential rather than as a body of work with a shape, a set of methods and a set of limits.

This page unpacks them. What each study set out to measure, what kind of study it is, where it was published or not published, how the three fit together, and — the section most supplement pages omit — what the three of them combined still do not show. If you only read one part, read the last two sections.

First: what “a study” is worth depends on four things

Before the studies themselves, the grading tool. When any product cites research, four questions do almost all the work of telling you how much weight the citation carries. They are worth learning once and applying everywhere.

1. Was it peer-reviewed? Independent researchers with no stake in the result assessed the methods before publication, and anyone can now read them. Peer review is a filter, not a guarantee — but a study that has passed it and a document that has not are not the same object.
2. Was it in humans? Cell-culture and animal work is real science and a legitimate starting point. It is not evidence about people, and the slide from one to the other is the most common overstatement in supplement marketing.
3. Did it measure an outcome or a marker? An outcome is something a person experiences — fewer sick days, faster recovery. A marker is a laboratory number standing in for a process. Markers are cheaper, faster and far weaker.
4. Did it test the finished product? Research on an ingredient at a different dose, in a different form, is not research on the thing in the bottle.

Applied to Max, those four questions produce an answer that is neither the marketing version nor the dismissive version. Two of the four are strongly satisfied across all three studies — they are human, and they tested the finished formula. One is satisfied by a single study. One is not satisfied by any of them.

Study one — Yu et al., 2024: the first two hours

The peer-reviewed one. Published in Current Issues in Molecular Biology (2024, volume 46, pages 6710–6724), it carries a title that does a lot of honest work in a single line: Feasibility Trial Exploring Immune-Related Biomarkers Pertaining to Rapid Immune Surveillance and Cytokine Changes after Consuming a Nutraceutical Supplement Containing Colostrum- and Egg-Based Low-Molecular-Weight Peptides.

Read the title slowly and it tells you almost everything, including the limits.

• “Feasibility trial” is a formal category, not modesty. A feasibility trial is a small, early-stage human study whose job is to establish whether a measurement approach works and whether any signal is present — explicitly in order to justify a larger, properly powered study later. It is the first rung, and it is labelled as such by the authors themselves.
• “Exploring” is likewise the language of hypothesis generation rather than confirmation.
• “Immune-related biomarkers” tells you the endpoint was a laboratory measurement, not a health event.
• “Rapid immune surveillance” is the timescale — this is the study behind the widely repeated figure of a measurable change within roughly two hours of a single dose.
• “Colostrum- and egg-based low-molecular-weight peptides” is a description of the molecular size class of the active material — independent corroboration of what the ingredient is, though not of what it does.

What the study supports, stated at full strength and no further: in a small feasibility trial, a single dose of the finished formula was followed by measurable changes in certain immune biomarkers and cytokines within a short window.*

What it does not support: that the immune system became more effective. Speed is not magnitude, a biomarker is not a benefit, and a feasibility trial is by design not the study that settles a question. The two-hour figure has been repeated across the industry with a confidence the original paper never claimed for it.

Study two — Jensen, 2026: the front line

Documented as 4Life Research Clinical Report 058-010, the Jensen work examined neutrophil activation following supplementation with the Max formula.

Neutrophils are a well-chosen target. They are the most abundant white blood cell in the body and the innate immune system's first responders — the cells that arrive first and do the immediate, physical work of defence. Crucially for a study, their activation state is measurable: the surface markers a neutrophil displays shift as it moves toward its fighting state, which turns the vague idea of “immune readiness” into a number that can be recorded.

The honest annotation belongs here rather than in a footnote. This is a company clinical report, not a peer-reviewed publication. That does not make it wrong, and it does not make it dishonest to cite — company research is how most product development is done in every industry. It does mean that no independent reviewer assessed the methods, and that a reader outside 4Life cannot pull up the full protocol and check the design, the sample, or the controls. Where that verification is unavailable, the correct reading is the cautious one.

Study three — Gardner, 2026: the factory

The Gardner report examined immune stem cell mobilisation — the behaviour of hematopoietic stem cells, the bone-marrow population from which the entire immune system is continually rebuilt.

This is the study that gave the 4Life framework its fourth verb. Recognize. Respond. Remember. Now renew. The first three describe what existing immune cells do. Renew describes where the next generation of them comes from, and the Gardner work is the reason that verb appears in the Max era rather than earlier.*

It is also the study with the longest horizon of the three, and it connects directly to the second: neutrophils are themselves produced from hematopoietic stem cells. Jensen looked at the front line; Gardner looked at the factory that supplies it. Same pipeline, two ends.

The same evidentiary annotation applies. Gardner is a 4Life Research clinical report, not a peer-reviewed paper.

The three side by side

The arc is real and it is the most defensible thing about the set. Three studies at three timescales, examining a system rather than a moment, is a more thoughtful research design than a single study repeated three times would have been. It is a legitimate reason the Max formula is discussed as a modulation story rather than a boosting one — the endpoints chosen were about how a system behaves over time, not about how much of something went up.

What the three studies do not show

Four gaps, named specifically. Each is the kind of thing a careful reader should notice missing, and each is missing.

• No health outcome was measured. Not illness, not infection rates, not recovery time, not duration of symptoms, not disease risk. Every endpoint across all three studies is a laboratory marker. The gap between “a marker changed” and “a person was better off” is the single widest gap in nutrition science, and nothing here crosses it.*
• No ingredient was isolated. The formula contains 900 mg of transfer factor plus a Cordyvant blend, IP-6, a super-mushroom blend, and vitamins C and D3 with zinc. Nothing published attributes any observed change to the transfer factor specifically rather than to the blend as a whole.
• Two of three lack independent review. Jensen and Gardner have not been through peer review and their full methods are not publicly retrievable. A reader cannot check them, and a claim that cannot be checked should be weighted accordingly.
• No mechanism was established. No receptor was identified, no binding study published, no pathway mapped. The studies observed cells changing behaviour. They did not show how.*

And one phrase to retire: “clinically proven”. It appears constantly in this category and it is almost never earned. Clinically studied is accurate here and is a real distinction — most supplements on the shelf have no human research on the finished product at all. Clinically proven implies established outcomes from adequately powered controlled trials, which is not what any of these three studies were designed to produce. This site uses the first phrase and not the second.*

So what is a fair summary?

That three human studies were conducted on a finished supplement formula, at three different biological timescales, and that one of them cleared peer review in a scientific journal. Measured against the supplement category — where the overwhelming majority of products cite no human research on the actual product — that is a meaningfully above-average evidence base and an honest reason to take the formula seriously.

Measured against pharmaceutical standards, it is early-stage work: small, exploratory, biomarker-based, and two-thirds unreviewed. Both statements are true at once, and any page that gives you only one of them is selling rather than explaining.

The right conclusion is proportionate. This is a well-researched product for a dietary supplement, and it is a dietary supplement — intended to support the immune system's normal functions, not to do anything to a disease. Anyone deciding about it deserves to have both halves of that sentence.*

Frequently asked questions

Citations & sources

Keep reading

*These statements have not been evaluated by the Food and Drug Administration. Transfer Factor Max and the other products mentioned are dietary supplements and are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. This article is general education about the published research record and how to read it; it is not medical advice, and nothing in it should be taken as a claim that any product affects any disease. Follow label directions; do not exceed the recommended daily amount. Consult your healthcare provider before beginning any new supplement program, particularly if you take medication, have an autoimmune condition, have an egg or dairy allergy, or are pregnant or nursing.